Li Zhang1, Jia Liu2, Yanchun Liu1, Yaguang Xu1, Xiufen Zhao1, Jun Qian1, Bin Sun1, Changying Xing1. 1. Department of Nephrology, First Affiliated Hospital, Nanjing Medical University, 300 Guangzhou Road, Nanjing, 210029, China. 2. Department of Nephrology, First Affiliated Hospital, Nanjing Medical University, 300 Guangzhou Road, Nanjing, 210029, China. jiajj3@sina.com.
Abstract
BACKGROUND: Previous studies showed that statins may have protective effects on peritoneal mesothelial cells (PMC) cultured in high glucose. However, the mechanisms are not clear yet. Several studies demonstrated that serum- and glucocorticoid-inducible kinase 1 (SGK1) is implicated in tissue fibrosis of liver, lung and kidney by regulating the expression of many profibrogenic cytokines and extracellular matrix (e.g., fibronectin). However, few available reports elucidated whether the SGK1 is involved in the pathogenesis of peritoneal fibrosis (PF) in patients with peritoneal dialysis (PD). So far, there is no study about the interaction between the statins and SGK1 in PMC. The purpose of this study was to identify whether fluvastatin may decrease the expression of fibronectin (FN) in human peritoneal mesothelial cells (HPMC) cultured with high-glucose peritoneal dialysis solution (HGPDS) by affecting SGK1 signal pathway. METHODS: Cultured HPMC were divided into groups of control, high-glucose peritoneal dialysis solution (HGPDS), HGPDS with fluvastatin (10(-8) mol/L ~ 10(-6) mol/L) or GSK650394 10(-5) mol/L (the competitive inhibitor of SGK1), fluvastatin 10(-6) mol/L or GSK650394 10(-5) mol/L alone. The expression of SGK1 and FN was detected by RT-PCR, western immunoblotting or ELISA. RESULTS: Compared with the control, the mRNA and protein expression of SGK1 and FN increased significantly in HPMC treated with HGPDS (p < 0.05). GSK650394 significantly decreased the upregulated mRNA and protein expression of SGK1 and FN induced by HGPDS (p < 0.05), and fluvastatin had the same effects as GSK650394 in a dose-dependent manner (p < 0.05). CONCLUSIONS: Expression of SGK1 and FN increased in HPMC induced by HGPDS. Treated with fluvastatin and the SGK1-inhibitor GSK650394, abnormalities of SGK1 and FN could be corrected partially, which suggested that the SGK1 pathway was implicated in the pathogenesis of PF, and that fluvastatin might decrease the expression of SGK1 so as to meliorate the progression of PF.
BACKGROUND: Previous studies showed that statins may have protective effects on peritoneal mesothelial cells (PMC) cultured in high glucose. However, the mechanisms are not clear yet. Several studies demonstrated that serum- and glucocorticoid-inducible kinase 1 (SGK1) is implicated in tissue fibrosis of liver, lung and kidney by regulating the expression of many profibrogenic cytokines and extracellular matrix (e.g., fibronectin). However, few available reports elucidated whether the SGK1 is involved in the pathogenesis of peritoneal fibrosis (PF) in patients with peritoneal dialysis (PD). So far, there is no study about the interaction between the statins and SGK1 in PMC. The purpose of this study was to identify whether fluvastatin may decrease the expression of fibronectin (FN) in human peritoneal mesothelial cells (HPMC) cultured with high-glucose peritoneal dialysis solution (HGPDS) by affecting SGK1 signal pathway. METHODS: Cultured HPMC were divided into groups of control, high-glucose peritoneal dialysis solution (HGPDS), HGPDS with fluvastatin (10(-8) mol/L ~ 10(-6) mol/L) or GSK650394 10(-5) mol/L (the competitive inhibitor of SGK1), fluvastatin 10(-6) mol/L or GSK650394 10(-5) mol/L alone. The expression of SGK1 and FN was detected by RT-PCR, western immunoblotting or ELISA. RESULTS: Compared with the control, the mRNA and protein expression of SGK1 and FN increased significantly in HPMC treated with HGPDS (p < 0.05). GSK650394 significantly decreased the upregulated mRNA and protein expression of SGK1 and FN induced by HGPDS (p < 0.05), and fluvastatin had the same effects as GSK650394 in a dose-dependent manner (p < 0.05). CONCLUSIONS: Expression of SGK1 and FN increased in HPMC induced by HGPDS. Treated with fluvastatin and the SGK1-inhibitor GSK650394, abnormalities of SGK1 and FN could be corrected partially, which suggested that the SGK1 pathway was implicated in the pathogenesis of PF, and that fluvastatin might decrease the expression of SGK1 so as to meliorate the progression of PF.
Entities:
Keywords:
Fibronectin; Fluvastatin; High-glucose peritoneal dialysis solution; Human peritoneal mesothelial cells; Serum- and glucocorticoid-inducible kinase 1
Authors: Simone Waerntges; Karin Klingel; Cora Weigert; Sophie Fillon; Miriam Buck; Erwin Schleicher; Hans P Rodemann; Cornelius Knabbe; Reinhard Kandolf; Florian Lang Journal: Cell Physiol Biochem Date: 2002
Authors: K Klingel; S Wärntges; J Bock; C A Wagner; M Sauter; S Waldegger; R Kandolf; F Lang Journal: Am J Physiol Gastrointest Liver Physiol Date: 2000-11 Impact factor: 4.052
Authors: Blanca Carrión; Francisco C Pérez-Martínez; Silvia Monteagudo; María D Pérez-Carrión; Carmen Gómez-Roldán; Valentín Ceña; Juan Pérez-Martínez Journal: Perit Dial Int Date: 2011-02-28 Impact factor: 1.756
Authors: Steven E Mutsaers; Kimberly Birnie; Sally Lansley; Sarah E Herrick; Chuan-Bian Lim; Cecilia M Prêle Journal: Front Pharmacol Date: 2015-06-09 Impact factor: 5.810
Authors: Raquel Díaz; Pilar Sandoval; Raul R Rodrigues-Diez; Gloria Del Peso; José A Jiménez-Heffernan; Ricardo Ramos-Ruíz; Carlos Llorens; Gustavo Laham; Mabel Alvarez-Quiroga; Manuel López-Cabrera; Marta Ruiz-Ortega; María A Bajo; Rafael Selgas Journal: Int J Mol Sci Date: 2020-08-13 Impact factor: 5.923
Authors: Vanessa Marchant; Antonio Tejera-Muñoz; Laura Marquez-Expósito; Sandra Rayego-Mateos; Raul R Rodrigues-Diez; Lucia Tejedor; Laura Santos-Sanchez; Jesús Egido; Alberto Ortiz; Jose M Valdivielso; Donald J Fraser; Manuel López-Cabrera; Rafael Selgas; Marta Ruiz-Ortega Journal: Biomolecules Date: 2020-09-24